| New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk J Dupuis, C Langenberg, I Prokopenko, R Saxena, N Soranzo, ... Nature genetics 42 (2), 105-116, 2010 | 2493 | 2010 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2228 | 2019 |
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling SM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M Lynch Molecular cancer therapeutics 7 (10), 3129-3140, 2008 | 1644 | 2008 |
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ... Nature genetics 47 (5), 505-511, 2015 | 1636 | 2015 |
| Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014 | 1625 | 2014 |
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma Y Hoshida, A Villanueva, M Kobayashi, J Peix, DY Chiang, A Camargo, ... New England Journal of Medicine 359 (19), 1995-2004, 2008 | 1329 | 2008 |
| Genetic landscape and biomarkers of hepatocellular carcinoma J Zucman-Rossi, A Villanueva, JC Nault, JM Llovet Gastroenterology 149 (5), 1226-1239. e4, 2015 | 1214 | 2015 |
| Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Y Hoshida, SMB Nijman, M Kobayashi, JA Chan, JP Brunet, DY Chiang, ... Cancer research 69 (18), 7385-7392, 2009 | 1179 | 2009 |
| Liver cancer cell of origin, molecular class, and effects on patient prognosis D Sia, A Villanueva, SL Friedman, JM Llovet Gastroenterology 152 (4), 745-761, 2017 | 1068 | 2017 |
| Pivotal role of mTOR signaling in hepatocellular carcinoma A Villanueva, DY Chiang, P Newell, J Peix, S Thung, C Alsinet, V Tovar, ... Gastroenterology 135 (6), 1972-1983. e11, 2008 | 826 | 2008 |
| Human polymorphism at microRNAs and microRNA target sites MA Saunders, H Liang, WH Li Proceedings of the National Academy of Sciences 104 (9), 3300-3305, 2007 | 775 | 2007 |
| Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features D Sia, Y Jiao, I Martinez-Quetglas, O Kuchuk, C Villacorta-Martin, ... Gastroenterology 153 (3), 812-826, 2017 | 750 | 2017 |
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ... Cancer research 68 (16), 6779-6788, 2008 | 733 | 2008 |
| Genomics and signaling pathways in hepatocellular carcinoma A Villanueva, P Newell, DY Chiang, SL Friedman, JM Llovet Seminars in liver disease 27 (01), 055-076, 2007 | 715 | 2007 |
| Advances in targeted therapies for hepatocellular carcinoma in the genomic era JM Llovet, A Villanueva, A Lachenmayer, RS Finn Nature reviews Clinical oncology 12 (7), 408-424, 2015 | 685 | 2015 |
| Pikarsky Eet al. et al JM Llovet, J Zucman-Rossi Hepatocellular carcinoma. Nature Reviews Disease Primers 2, 16018, 2016 | 610* | 2016 |
| Tumour evolution in hepatocellular carcinoma AJ Craig, J Von Felden, T Garcia-Lezana, S Sarcognato, A Villanueva Nature reviews Gastroenterology & hepatology 17 (3), 139-152, 2020 | 601 | 2020 |
| β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma M Ruiz de Galarreta, E Bresnahan, P Molina-Sánchez, KE Lindblad, ... Cancer discovery 9 (8), 1124-1141, 2019 | 566 | 2019 |
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes D Sia, Y Hoshida, A Villanueva, S Roayaie, J Ferrer, B Tabak, J Peix, ... Gastroenterology 144 (4), 829-840, 2013 | 560 | 2013 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 530 | 2019 |
